Intercept Pharma

$16.69 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Intercept Pharma

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Stock Analysis

last close $16.9
1-mo return -18.7%
3-mo return -20.2%
avg daily vol. 478.61T
52-week high 55.59
52-week low 13.88
market cap. $560M
forward pe -
annual div. -
roe -143255%
ltg forecast -
dividend yield -
annual rev. $322M
inst own. 76.4%
baraka

Subscribe now for daily local and international financial news

Subscribe